

# Pharmacy Initiative 2009

Michael Strampel, Pharm.D.

December 5, 2008



# Current Pharmacy Measurers 2008

- Generic Dispensing Rate (GDR or GUR)
- Therapeutic Categories
  - Proton Pump Inhibitors PMPM
  - Non-Sedating Antihistamines PMPM
  - Statin PUMPM
  - Antidepressant PUMPM



# Pharmacy Measurers 2009

## Generic Dispensing Rate (GDR)

- Rate is based on all rendered claims (claims written by the physician under their DEA number not just those claims for attributed patients)
- GDR Improvement represents the increase in each physician group's GDR from baseline to current time period
- Trend over time compared to trend over time of ABC value
  - ABC Benchmark calculated as the average of the top performing groups treating 10% of the attributed population
- Participation alone no longer a performance measure
- Simpler measure but essentially not different than 2008



# Pharmacy Initiative

- Will continue to be a significant initiative for 2009
- Will be part of PC-MH determinations (GDR)
- EBCR also includes pharmacy measures
  - Gaps in care
- Base pharmacy benefit changes will continue to impact control group trend
- Opportunities continue for existing generic products
- New opportunities for 2009 available as patents expire



# Methodology

- Group specific target improvement will be reported but will not be a performance measure
  - No forward looking reference available
  - Reported value will continue as 3% for 2009
- Available comparator values for trend include:
  - PGIP group specific trend
  - ABC trend
  - Reference plan trend (Regence BCBS)
  - Non participating control group trend
  - Book of Business trend
  - BCN trend



# Methodology

- ABC Benchmark (trend)
  - ABC Benchmark calculated as the average of the top performing groups treating 10% of the attributed population (Based on data from 3<sup>rd</sup> Quarter)
  - ABC Benchmark will be calculated and measured against at the beginning of each calendar year



# Reporting

- Quarterly reporting will continue
- Rolling 6 month values will continue
- All therapeutic categories from 2008 will continue to be reported
- New therapeutic categories in dashboard will include:
  - Intranasal Steroids
  - ACE/ARB
- Physician specific opportunities reporting will not be available initially in 2009 but is under development



# Trend


ABC Performance  
Trend

PGIP Group Trend



# GDR Improvement by Program

## PGIP Generic Dispensing Rate Improvement



# GDR rate of change

<u>Period</u>	<u>Generic Prescriptions</u>	<u>Total Prescriptions</u>	<u>GDR</u>	<u>Difference to prior</u>
2008q3	4,335,215	6,697,243	64.73%	0.72%
2008q2	4,206,658	6,572,134	64.01%	0.12%
2008q1	3,179,517	4,977,088	63.88%	2.54%
2007q4	3,438,847	5,606,357	61.34%	2.33%
2007q3	3,407,000	5,773,309	59.01%	

\* Based on physician rendered prescriptions

\* Periods represent PGIP 6 month reporting period



# Current Opportunities

## Summary

### DRUG CLASS

### Brand Prescriptions

Allegra-D	28,143
ARB	143,161
Clarinet	13,995
Crestor	10,804
Effexor XR	38,118
Lexapro	49,968
Lipitor	131,679
NasalSt	50,470
PPI	125,651
Xyzal	5,962
Total	<b>597,951</b>



# 2009 Generic opportunities

- Imitrex Tablets , Injection (December 2008)
- Lamictal
- Ambien CR
- Topamax
- Flomax (4<sup>th</sup> quarter)
- Prevacid (4<sup>th</sup> quarter)
- Valtrex (4<sup>TH</sup> quarter)
- Adderal XR ?? April 2009 possible



# 2009 Summary

- All measurers continue to focus on Generic Utilization
- Former therapeutic categories to be considered “initiatives” within the GDR measurement with separate reporting but performance included in GDR calculation
- Continued communication and representation from the groups and regional work groups essential

